Search Back New search Go to resultsDiseaseMain groupHematologic NeoplasmsProtocol groupT-Cell and NK-Cell NeoplasmsDiseaseNHL, T-cell typeNHL, T-Cell Type, Adult T-Cell Leukemia or LymphomaNHL, T-Cell Type, Anaplastic Large CellNHL, T-Cell Type, Anaplastic Large Cell Lymphoma, ALK-positiveNHL, T-Cell Type, Anaplastic Large Cell Lymphoma, ALK negativeNHL, T-Cell Type, AngioimmunoblasticNHL, T-Cell Type, Enteropathy TypeNHL, T-Cell Type, HepatosplenicNHL, T-Cell Type, Peripheral, UnspecifiedSubgroupCD30+ICD10C84.4C84.5C84.6C84.7C86.1C86.2C86.5C91.5-MeSHLymphoma, Non-HodgkinLymphoma, Primary Cutaneous Anaplastic Large CellLymphoma, T-CellLymphoma, T-Cell, CutaneousLymphoma, T-Cell, PeripheralSequenceChemotherapyChemo-substanceBendamustineBrentuximab vedotinCarboplatinCisplatinCyclophosphamideDexamethasoneDoxorubicinEtoposideGemcitabineIfosfamideLenalidomidePrednisoloneVincristineChemo-substanceBendamustineBrentuximab vedotinCarboplatinCisplatinCyclophosphamideDexamethasoneDoxorubicinEtoposideGemcitabineIfosfamideLenalidomidePrednisoloneVincristineChemo-substanceBendamustineBrentuximab vedotinCarboplatinCisplatinCyclophosphamideDexamethasoneDoxorubicinEtoposideGemcitabineIfosfamideLenalidomidePrednisoloneVincristineChemo-substanceBendamustineBrentuximab vedotinCarboplatinCisplatinCyclophosphamideDexamethasoneDoxorubicinEtoposideGemcitabineIfosfamideLenalidomidePrednisoloneVincristineNo. Substances134 RadiotherapySupportive therapySupportive substanceAciclovirBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneFosaprepitantGranisetronMagnesium sulfateMesnaPegfilgrastimPotassium chlorideSupportive substanceAciclovirBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneFosaprepitantGranisetronMagnesium sulfateMesnaPegfilgrastimPotassium chlorideSupportive substanceAciclovirBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneFosaprepitantGranisetronMagnesium sulfateMesnaPegfilgrastimPotassium chlorideSupportive substanceAciclovirBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneFosaprepitantGranisetronMagnesium sulfateMesnaPegfilgrastimPotassium chlorideNo. Substances46Protocol classificationTherapy classificationalternativecurrent standardIntensityStandard doseTherapy indicationFirst lineRelapse therapySecond lineseveral possibleTherapy phaseTherapy intentioncurativepalliativeRisksAllergic ReactionAnemia Hb below 8g/dlCardiotoxicityDiarrheaEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)Febrile NeutropeniaHyperbilirubinemiaIncrease AminotransferasesInfectionsMucositisNeuropathyNeutropeniaPneumonitisPruritusPyrexiaThrombocytopenia below 50 000/µlThromboembolic Event only studiesPublicationAuthorDamaj GHorwitz SQi FSimon AToumishey EVan de Wyngaert ZDiseaseperipheres T-Zell Lymphom, CD30+, Erstlinie, ECOG 0-2peripheres T-Zell Lymphom, Zweitlinie nach CHOP, ECOG 0-2PTCL oder CTCL, Stadium IIB oder höher, max. 3 Vortherapien, ECOG 0-2rezidiviertes oder refraktäres peripheres T-Zell Lymphom, CD30+, ECOG 0-3T-Zell-Lymphom, mind. 1 Vortherapie, ECOG 0-2T-Zell Lymphom, Erstlinie, ECOG 0-2OriginCentre Hospitalier Universitaire, Amiens, France, BENTLY TrialCentre Hospitalo-Universitaire (CHU) Grenoble, GOELAMS-LTP95 trialDalhousie University, Saint John, New Brunswick, CanadaDepartment of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), BeijingHématologie clinique et thérapie cellulaire, Hôpital Saint Antoine, APHP, Sorbonne Université, INSERM UMRs 938, Paris, FranceMemorial Sloan Kettering Cancer Center, New York, ECHELON-2 study groupProtocols in Revision 6 protocols foundProtocols under revision.Bendamustine 120, T-cell Lymphoma (PID1923)BV-ICE - Brentuximab Vedotin 1.8 / Etoposide 100 / Carboplatin 5 / Ifosfamide 5, T-cell Lymphoma (PID2420)CHOP 21 - Cyclophosphamide 750 / Doxorubicin 50 / Vincristine 2 / Prednisolone 100, T-cell Lymphoma, Variant 1 (PID1773)Cyclophosphamide 750 / Doxorubicin 50 / Prednisolone 100 / Brentuximab Vedotin 1.8, T-cell Lymphoma (PID1204)GDP - Gemcitabine 1000 / Dexamethasone 40 / Cisplatin 25, T-cell Lymphoma (PID2435)Lenalidomide 25, T-cell Lymphoma (PID2462)
